These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30097235)

  • 1. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.
    Banna GL; Passiglia F; Colonese F; Canova S; Menis J; Addeo A; Russo A; Cortinovis DL
    Crit Rev Oncol Hematol; 2018 Sep; 129():27-39. PubMed ID: 30097235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Assi HI; Kamphorst AO; Moukalled NM; Ramalingam SS
    Cancer; 2018 Jan; 124(2):248-261. PubMed ID: 29211297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on immune checkpoint inhibitors in lung cancer.
    Creelan BC
    Cancer Control; 2014 Jan; 21(1):80-9. PubMed ID: 24357746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
    Flynn MJ; Larkin JMG
    Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.
    Remon J; Besse B
    Curr Opin Oncol; 2017 Mar; 29(2):97-104. PubMed ID: 28059852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.
    Remon J; Vilariño N; Reguart N
    Cancer Treat Rev; 2018 Mar; 64():21-29. PubMed ID: 29454155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of response to immune checkpoint blockade in cancer treatment.
    Fujii T; Naing A; Rolfo C; Hajjar J
    Crit Rev Oncol Hematol; 2018 Oct; 130():108-120. PubMed ID: 30196907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    Villaruz LC; Socinski MA
    Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities.
    Ilie M; Benzaquen J; Hofman V; Lassalle S; Yazbeck N; Leroy S; Heeke S; Bence C; Mograbi B; Glaichenhaus N; Marquette CH; Hofman P
    Curr Mol Med; 2017; 17(8):527-540. PubMed ID: 29473504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.
    Melosky B; Chu Q; Juergens RA; Leighl N; Ionescu D; Tsao MS; McLeod D; Hirsh V
    Cancer Treat Rev; 2018 Apr; 65():65-77. PubMed ID: 29567557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
    Attili I; Passaro A; Pavan A; Conte P; De Marinis F; Bonanno L
    Crit Rev Oncol Hematol; 2017 Nov; 119():30-39. PubMed ID: 29065983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Dempke WC; Sellmann L; Fenchel K; Edvardsen K
    Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune check-point in cervical cancer.
    De Felice F; Marchetti C; Palaia I; Ostuni R; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2018 Sep; 129():40-43. PubMed ID: 30097236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.
    Provencio M; Carcereny E; Artal Á
    Clin Transl Oncol; 2019 Nov; 21(11):1464-1471. PubMed ID: 30903517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.